---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-325991"
form_type: "8-K"
ticker: "NUVB"
cik: "0001811063"
company_name: "Nuvation Bio Inc."
filed_at: "2021-11-10T23:59:59+00:00"
generated_at: "2026-06-28T10:10:09.777071+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Nuvation Bio Q3 2021 net loss $22.0M; cash $791.8M; NUV-422 enrollment ongoing

## Summary
- Net loss of $22.0M ($0.11 per share) vs $11.0M ($0.12) in Q3 2020.
- R&D expenses $17.1M, up from $8.6M; G&A $5.7M, up from $2.9M.
- Cash, equivalents and marketable securities $791.8M as of Sept 30, 2021.
- Enrollment ongoing in Phase 1/2 study of NUV-422; top-line data expected 2022.

## SEC filing metadata
- accession: 0001193125-21-325991
- form_type: 8-K
- ticker: NUVB
- cik: 0001811063
- company_name: Nuvation Bio Inc.
- filed_at: 2021-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811063/000119312521325991/0001193125-21-325991-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811063/000119312521325991/d439428d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-325991
- JSON: https://secwatch.observer/filing/0001193125-21-325991.json
- Plain text: https://secwatch.observer/filing/0001193125-21-325991.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.